Evoke Pharma (NASDAQ:EVOK) Major Shareholder Roger Klein Sells 9,000 Shares

Evoke Pharma, Inc. (NASDAQ:EVOK) major shareholder Roger Klein sold 9,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $10.65, for a total transaction of $95,850.00. Following the completion of the transaction, the insider directly owned 29,000 shares of the company’s stock, valued at approximately $308,850. This trade represents a 23.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Evoke Pharma Stock Up 0.6%

Evoke Pharma stock opened at $10.69 on Friday. Evoke Pharma, Inc. has a 52-week low of $1.94 and a 52-week high of $10.79. The firm’s fifty day moving average is $5.39 and its 200 day moving average is $4.41. The company has a market cap of $16.68 million, a price-to-earnings ratio of -4.18 and a beta of -0.14.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.32). The business had revenue of $3.75 million during the quarter, compared to analysts’ expectations of $3.80 million. Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EVOK. Wall Street Zen upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, September 7th. Laidlaw lowered Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evoke Pharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. National Wealth Management Group LLC bought a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned 5.14% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.